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Abstract: Liensinine is a bisbenzylisoquinoline alkaloid found in various parts of the lotus (Nelumbo nu-
cifera Gaertn.) including seeds. In this study, we explored the preventive activity of liensinine on
vascular inflammation via attenuation of inflammatory mediators in macrophage and targeting
the proliferation and migration of human vascular smooth muscle cells (VSMC). Anti-oxidative
activity was evaluated by using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scaveng-
ing assay method and measuring the peroxidation of serum lipid. Inflammatory markers were
studied by evaluating the release of nitric oxide (NO) and the protein levels of inducible nitric
oxide synthase (iNOS) and cyclooxygenase (COX-2) in macrophage cells (RAW264.7) and inter-
leukin (IL)-6 production in VSMC. Similarly, anti-proliferative activity in VSMC was evaluated by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The enzymatic activity of
matrix metalloproteinase (MMP)-9 in VSMC was evaluated by gelatin zymography. Liensinine pos-
sesses significant anti-oxidative activity as revealed by the DPPH assay and inhibition of serum
lipid peroxidation. Likewise, liensinine decreased NO generation in RAW 264.7 cells. In VSMC,
liensinine suppressed platelet-derived growth factor stimulated proliferation and tumor necrosis
factor-α (TNF-α) induced MMP-9 enzymatic activity as well as IL-6 expression. Our results revealed
the potential preventive effect of liensinine on vascular inflammation, suggesting it as a promising
compound for the prevention of vascular inflammation.
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1. Introduction
Atherosclerosis is defined as a chronic vascular inflammatory disorder that progresses
with the lipid oxidation due to hypercholesteremia, diabetes mellitus, hypertension and
various other disorders [1]. Oxidized lipids induce the secretion of various cytokines and
recruit macrophages and T-lymphocytes at the site of a lesion [2]. Further, accelerated vas-
cular smooth muscle cell (VSMC) migration and proliferation contribute to atherosclerotic
plaque development [3,4]. It is also stimulated by oxidative stress, which produces different
inflammatory cytokines; tumor necrosis factor-A(TNF-A), interleukin-6 (IL-6) and growth
factor such as platelet-derived growth factor-BB (PDGF-BB). According to the previous
study, treatment of IL-6 to C57Bl/6 mice increased fatty streak cores by approximately
five times as revealed by oil red o staining of aortic sinus serial section, and increased the
release of inflammatory cytokine, IL-1β and TNF-Ain the plasma [5]. Moreover, TNF-Aand
PDGF-BB are already reported to stimulate the migration of human aortic VSMC from
media to the intima of blood vessels [6]. These migrated cells are extensively proliferated
under the influence of inducing agents like PDGF, TNF-Aand lipopolysaccharide (LPS) in
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the intimal layer of arteries forming atheroma [7–9]. Mitogen-activated protein kinases
(MAPKs), a family of serine-threonine kinases, regulate cell adhesion, migration and prolif-
eration on human aortic VSMC in response to external stimuli including TNF-A [10] and
PDGF-BB [11,12]. The role of matrix metalloproteinase (MMP) is well known due to their
function for disrupting matrices composed of gelatin or elastin, which could permit human
aortic VSMC migration by destroying the elastic lamina present between the intima and
media [13,14]. Vascular inflammation is a result of toxic insult by the mediators released by
the macrophage. Initially, monocytes normally circulating in the blood vessel are migrated
to tunica media due to endothelial dysfunction. At this site, they engulf the oxidized low-
density lipoprotein (ox-LDL) and become activated after changing the morphology from
macrophage to foam cell, as recognized by the accumulation of fatty streaks on lipid laden
molecules [15,16]. Activated macrophages release inflammatory mediators like nitric oxide
(NO) via the inducible nitric oxidase pathway, and prostaglandins via cyclooxygenase
pathway. Collectively, these endogenous inflammatory agents trigger the formation of a
necrotic core at the site of an atherosclerosis lesion [17,18].
Liensinine is a bisbenzylisoquinoline alkaloid found in various part of the lotus
(Nelumbo nucifera Gaertn.) including seeds (Figure 1). Liensinine and other bisbenzyliso-
quinoline alkaloids present in lotuses are reported as potent anticancer, anti-inflammatory,
antioxidant, cardiovascular protective and neuroprotective agents [19–21]. Traditionally,
the seed embryo of the lotus has been used as medicine in China for cardiovascular diseases,
nervous disorders and sleeplessness [22]. Previously, we reported the anti-atherosclerotic
activity of Nelumbo nucifera leaf extract and its alkaloid rich fraction through inhibition of
neointimal hyperplasia in rats and inhibiting VCMC proliferation and migration [12,23].
In the current study, we aim to determine the similarly beneficial activity of the liensinine
against vascular inflammation through anti-inflammatory, anti-proliferative, anti-migratory
and anti-oxidative activities.
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thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lipopolysaccharide (LPS) 
were obtained from Sigma Aldrich (St Louis, MO, USA). PDGF-BB and TNF-α were pur-
chased from R & D systems (Minneapolis, USA). All remaining common laboratory chem-
ical reagents or solvents were purchased from Sigma-Aldrich, South Korea. 
2.2. Cell culture 
VSMC from human aorta obtained from ATCC, USA and RAW264.7 cells purchased 
from Korean cell line bank (Seoul, Korea) were cultured in complete cell culture media 
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2. Materials and Methods
2.1. Reagents
Liensinine (Cas number: 2586-96-1) was purchased from Sigma Aldrich. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lipopolysaccharide
(LPS) were obtained from Sigma Aldrich (St Louis, MO, USA). PDGF-BB and TNF-α were
purchased from R & D systems (Minneapolis, MN, USA). All remaining common laboratory
chemical reagents or solvents were purchased from Sigma-Aldrich, South Korea.
2.2. Cell Culture
VSMC from human aorta obtained from ATCC, USA and RAW264.7 cells purchased
from Korean cell line bank (Seoul, Korea) were cultured in complete cell culture media
with Dulbecco’s odified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS), and 1%
antibiotics (penicillin + streptomycin) in a standard cell incubator with 5% CO2. The cells
were incubated in media with 0.1% FBS for 24 h to allow them to synchronize at G0 phase
for each assay. Liensinine was solubilized in dimethyl sulfoxide (DMSO) and diluted in a
serum-free medium for treatment of cells. The final % of DMSO while treating cells were
below 0.1%.
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2.3. DPPH Assay and Thiobarbituric Acid Reactive Substance (TBARS) Assay for Lipid
Peroxidation Assay
The anti-oxidant activity of liensinine was evaluated using a DPPH free radical scav-
enging assay and measurement of serum lipid peroxidation was carried out using TBARS
assay following the methods as described previously [11].
2.4. Proliferation Assay
PDGF-BB was used as a proliferation inducer in VSMC and % proliferation was mea-
sured by MTT colorimetric assay as described previously [24]. VSMC were treated with
liensinine 1 h before PDGF-BB and incubated for 24 h to allow proliferation. Freshly pre-
pared MTT in phosphate buffer saline was added and incubated for an additional 4 h.
The purple color formazan developed due to the reduction of MTT by viable VSMC were
dissolved with DMSO. Then, a colorimetric reading was taken by measuring absorbance at
540 nm with a microplate reader. The anti-proliferative effect of liensinine was evaluated
by comparison with the control group (treated with PDGF-BB) as 100%.
2.5. Gelatin Zymography
Gelatin zymography was carried out to examine the enzymatic activity of MMP-9 as
described previously [14]. Briefly, VSMC were seeded in 60 mm petri plates at the density of
1 × 106 cells. Liensinine was added at a predetermined concentration for 1 h and cells were
treated with TNF-α (100 ng/mL) for the next 24 h. The supernatant cell culture media was
collected and 30 µg of protein equivalent was used for electrophoresis in 10% SDS-PAGE
with 0.25% gelatin. Next, the gels were incubated in renaturating buffer (2.5% Triton X-100)
for half-an-hour and incubated again in developing buffer at 37 ◦C for 16–24 h. In order
to visualize the bands of MMP2 and MMP-9, gels were stained with 0.05% Coomassie
Brilliant Blue followed by incubation in destaining buffer. Photographs of the gel were
taken to observe the proteolysis of gelatin by MMP-2 and MMP-9.
2.6. Determination of IL-6 Release in TNF-α Stimulated VSMC
VSMC was pretreated with 1–30 µM of liensinine for 1 h and further treated with TNF-
α for the next 24 h. The level of IL-6 released by cells was measured in culture supernatant
using an ELISA kit of IL-6, according to manufacturer’s protocol.
2.7. Cell Viability/Cytotoxicity Assay, NO Release and Immunoblot of iNOS, and COX-2 Protein
Expression in RAW264.7 Cells
RAW264.7 cell viability or cytotoxicity assay was carried out using the MTT col-
orimetric assay as described in Section 2.4 (without any stimulant). The NO levels in
RAW264.7 cells were evaluated as mentioned previously [25]. Briefly, the cells were treated
with 1–20 µM of liensinine for 1 h, then induced with LPS at 1 µg/mL for the next 24 h.
The level of NO in culture supernatant was measured by mixing a 1:1 ratio (100 µL) of
supernatant: Griess reagent. The colored product was measured calorimetrically by read-
ing absorbance at 540 nm. For protein expression of iNOS and COX-2 in RAW 264.7 cells,
immunoblotting was carried out [26].
2.8. Statistical Analysis
Data analysis and graphs were prepared using SigmaPlot or Microsoft Excel. The data
are represented as mean ± standard error mean. Multiple groups were compared using
one-way analysis of variance (ANOVA) and Duncan’s post-hoc test. p-values of < 0.05 were
considered as statistically significant.
3. Results
3.1. Liensinine Scavenges DPPH Free Radicals and Inhibits Serum Lipid Peroxidation
Liensinine showed concentration-dependent DPPH free radical scavenging activity
as displayed in Figure 2a. The inhibitory concentration 50 (IC50) of liensinine was found
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to be 1.8 µg/mL. Figure 2b shows the measurement of serum lipid peroxidation. Liensi-
nine at concentrations of 30 and 40 µg/mL showed remarkable reduction of serum lipid
peroxidation in terms of TBARS value.
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3.2. Liensinine Inhibits VSMC Proliferation
PDGF-BB is a potent growth factor over-expressed in human coronary arteries during
atherosclerosis and restenosis [27]. Figure 3 shows the potent anti-proliferative activity of
liensinine against PDGF-BB stimulated VSMC proliferation. Liensinine, at a concentrations
of 20 and 30 µg/mL notably decreased the % cell proliferation to 67.16% and 47.02%,
respectively, vs. 100% of control (PDGF-BB only).
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3.3. Liensinine Inhibits MMP-9 Enzymatic Action
The degradation of the extracellular matrix by enzymatic action of MMPs (stimu-
lated by various mitogens) is responsible for VSMC migration. TNF-α is one such mi-
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togen/activator that stimulates MMP-9 enzyme activity in VSMCs [28]. The effect of
liensinine on the MMP-9 proteolytic degradation of gelatin in VSMCs is displayed in
Figure 4. The MMP-9 band was drastically increased by TNF-α (compared to without
TNF-α) and decreased concentration dependently by liensinine (compared to TNF-α).
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3.5. Liensinine Suppresses NO Production and Inhibit Protein Expression of iNOS and COX-2
in RAW264.7
First, we checked the cytotoxicity of vario s concentrations of liensinine in RAW264.7 cells.
Li n inine up to 20 µM did not exert any significa t decrease in RAW264.7 c ll viabil-
ity (Figure 6a). T e 24 h treatment of cell with LPS increased the production of NO
(95.2 ± 9.8 µM) by approx mat ly 3-fold compared to those without LPS treatment. Liensi-
nine showed inhibition of NO rel ase in a concentration-d pendent manner (Figure 6b).
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Consistent with NO production, there was an overexpression of iNOS (Figure 6c,d) and
COX-2 (Figure 6c,e) proteins after LPS treatment, while liensinine (5–20 µM) treatment
resulted in a notable reduction in protein expression.
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4. Discussion
In our study, we have shown that liensinine inhibits the key features of vascular in-
flammation mediated by altered VSMC function due to PDGF and TNF-α, and macrophage
function by LPS (Figure 7). During vascular inflammation, toxic insults to the blood vessel
wall are mediated by oxidative stress, lipid peroxidation, and inflammation mediators
released by VSMC and activated macrophage facilitates atherosclerosis progression [29,30].
Under stressful conditions, our bodies generate free radicals such as superoxide anion,
which in turn convert NO to peroxynitrite. Peroxynitrite facilitates the oxidative modifica-
tion of cholesterol to produce enormous quantities of lipid peroxidation byproducts [18].
Blood/serum lipids such as low-density lipoprotein (LDL) are involved in the progres-
sion/pathogenesis of numerous diseases including atherosclerosis. Oxidized-LDL up-
regulates the scavenger receptors on macrophages followed by the increased engulfment
of ox-LDL and conversion of macrophages to foam cells characterized by accumulation
of fatty streaks [31,32]. Therefore, pharmacological intervention inhibiting serum lipid
peroxidation can slow down the process of vascular inflammation. We have previously
shown that alkaloid rich fractions of Nelumbo nucifera possess strong antioxidant activity
and suppress restenosis in a rat model [12]. As liensinine is one of the major alkaloids
presents in Nelumbo nucifera, we sought to investigate if an antioxidant effect is exerted by
liensinine. In our antioxidant activity assay, liensinine showed potent activity as revealed
by scavenging the DPPH free radical with IC50 of 1.8 µg/mL (Figure 2a) and significantly
inhibiting serum lipid peroxidation with 30 and 40 µg/mL concentrations of liensinine
(Figure 2b). The DPPH antioxidant activity of liensinine was even better than another
major alkaloid, neferine, with IC50 of 10.665 µg/mL (17.01 µM) [33].
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In physiological systems, atherogenesis is initiated in major arteries after endothelial
dysfunction triggered by oxidative stress, leading to significant changes in the perme-
ability of the vascular intimal layer and resulting in transportation of ox-LDL to the
vascular inner layer [34]. After endothelial cells are activated by atherogenic risk factors
such as ox-LDL, they overexpress cell adhesion molecules such as intercellular adhesion
molecules and vascular cell adhesion molecules to attract circulating cells including mono-
cytes and leukocytes. The transported ox-LDL are engulfed by scavenger receptors of
macrophages/monocytes [35]. Macrophages are activated after phagocytosis of ox-LDL
and in turn overexpress iNOS and COX-2 [17,36]. It is well established that high iNOS level
corresponds with a massive release of NO from macrophages and subsequent inflamma-
tory response [37]. Similarly, LDL also stimulates the production of various prostaglandins
through the COX-2 pathway, and these prostaglandins are known to be mitogenic, simulat-
ing cell proliferation [38]. Our results showed promising activity of liensinine to suppress
NO release from LPS-induced RAW264.7. The 25% reduction of NO by liensinine at a con-
centration of 20 µg/mL (Figure 6b) was comparable to 20 µM of neferine [33]. Furthermore,
liensinine also notably decreased the protein expression of COX-2 and iNOS. The trend of
iNOS and COX-2 inhibition shown by liensinine was similar to that shown by glucosamine
(a commercially available anti-inflammatory drug) at a concentration of 2.5 to 10 mM in
LPS-induced RAW264.7 cells [39].
IL-6 is a well characterized inflammatory mediator and it is released by VSMC after the in-
duction of potent stimulants such as TNF-α [40] and angiotensin II [41]. IL-6 is crucial in vascular
remodelling and it, along with ox-LDL, is a potential prognostic marker in predicting cerebral vas-
cular and cardiovascular disorders [42]. In our ELISA result (Figure 5), liensinine suppressed
the TNF-α induced IL-6 level in VSMC by approximately 50% at 30 µg/mL concentration.
During atherosclerosis, the vascular lumen is narrowed by a fibrous cap composed of
(among many other things) VSMC and extracellular matrix. Various growth factors and cy-
tokines produced by endothelial cells and inflammatory cells contribute to the proliferation
and migration of VSMC leading to fibrous cap formation [29,43,44]. Cytokines like PDGF
can induce proliferation of VSMC to a significantly high level, whereas TNF-α is known to
stimulate the migration of VSMC from tunica media to the site of a lesion by increasing
MMP-9 expression. MMP-9 is a key gelatinolytic enzyme responsible for the degradation
of the elastic lamina barrier of the extra cellular matrix [45,46]. In our previous publications,
we have shown that PDGF and TNF-α promote the proliferation and MMP-9-dependent
migration of VSMC [11,12,14]. In our result, liensinine inhibited the PDGF-BB induced pro-
liferation/growth of VSMC, revealing its potent anti-proliferating activity. At a 30 µg/mL
concentration of liensinine, the proliferation of VSMC was almost completely inhibited to
the level of the control (without PDGF) (Figure 3). The potent anti-proliferative activity of
liensinine at a concentration of 30 µg/mL is comparable to 50 µM of epigallocatechin-
3-O-gallate [47] and 20mM of carnosine [48]. Likewise, liensinine at a concentration
of 10, 20 and 30 µg/mL significantly attenuated the expression of MMP-9 induced by
TNF-α (Figure 4). We speculate that the notable inhibition of MMP-9 enzymatic activity by
Nelumbo nucifera leaf extract in our previous study, at a concentration of 250 µg/mL, was in
part exerted by liensinine [23]. Taken together, our results provide the mechanistic pathway
to attenuate the progression of atherogenesis via controlling vascular inflammation by
liensinine possibly by targeting VSMC proliferation, MMP-9 expression and inflammatory
mediators released by macrophages (Figure 7).
5. Conclusions
Our results showed that liensinine can effectively prevent the progression of atheroscle-
rosis by modulating the mediators of vascular inflammation via inhibiting the migration
and proliferation of VSMC as well as attenuating the release of inflammatory mediators
from RAW264.7. Our research is limited to an in vitro experiment, therefore further re-
search is necessary to explore the protective role of liensinine in the pathophysiology of
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atherosclerosis. It would be worth conducting an in vivo study in a pre-clinical animal
model of atherosclerosis and exploring the promising activity of liensinine.
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